Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monotherapy With a P2Y12 Inhibitor Followed by a Direct-acting Oral Anticoagulant in Patients With ATRial fIbrillation Undergoing suprafleX Cruz Coronary Stent Implantation

NCT05955365 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT05955365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05955365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monotherapy With a P2Y12 Inhibitor Followed by a Direct-acting Oral Anticoagulant in Patients With ATRial fIbrillation Undergoing suprafleX Cruz Coronary Stent Implantation
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Phase 4
Overall status
Recruiting
Start date
December 18, 2023
Completion date
June 30, 2028
Enrollment
3,010 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af), oral anticoagulation, p2y12 inhibitor, percutaneous coronary intervention (pci)